載入中
Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.
前收盤價
US$62.06
+US$1.29 · +2.12%
盤中時間採用ET。市場資料可能有所延遲。
Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.
日內區間
目前US$62.06
52週區間
目前US$62.06
盤中時間採用ET。市場資料可能有所延遲。
Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.
日內區間
目前US$62.06
52週區間
目前US$62.06
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 1.71億 USD | 9667.1萬 USD | 6926.4萬 USD | 3343.7萬 USD | 2517萬 USD |
| 銷售、一般及管理費用 | 6538.2萬 USD | 3304.9萬 USD | 2186.1萬 USD | 1403.8萬 USD | 576.3萬 USD |
| 營業費用 | 2.36億 USD | 1.3億 USD | 9112.5萬 USD | 4747.5萬 USD | 3093.3萬 USD |
| 利息收入 | 2776.1萬 USD | 2129.2萬 USD | 1479.7萬 USD | 70.9萬 USD | 1.4萬 USD |
| 利息支出 | 360.7萬 USD | 57.2萬 USD | — | — | 215.8萬 USD |
| 折舊和攤銷 | 28.1萬 USD | 15.6萬 USD | 10萬 USD | 8.9萬 USD | 3.2萬 USD |
| 營業利益 | −2.36億 USD | −1.3億 USD | −9112.5萬 USD | −4747.5萬 USD | −3093.3萬 USD |
| 淨利 | −2.12億 USD | −1.09億 USD | −7642.9萬 USD | −4682.7萬 USD | −3596.9萬 USD |
公司資料更新於 2026年10月11日。
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2022年12月30日 | 1:10 | — | — |
已生效 2022年12月30日
1:10
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI7665.3萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM4526.42萬0.06%787.4億 USD0.19%US$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI4433.13萬0.45%98.74億 USD0.35%US$153.77+3.00%
Vanguard Extended Market ETFVXF2925.91萬0.03%954億 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO1589.74萬0.12%139.17億 USD0.24%US$356.78+0.94%
Dimensional - US Small Cap ETFDFAS1452.63萬0.04%338.69億 USD0.31%US$78.35+0.32%
iShares Biotechnology ETFIBB1335.29萬0.13%108.2億 USD0.44%US$206.49+3.00%
Vanguard Russell 2000 ETFVTWO1279.26萬0.07%180億 USD0.06%US$112.66+0.50%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWODimensional - US Small Cap ETFDFASiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
